VIENNA, Aug 8 (Reuters) - Austrian biotech firm Intercell <ICEL.VI> is looking for further acquisitions after its takeover of U.S. peer Iomai <IOMI.O> and could become a target in the sector consolidation itself, Werner Lanthaler told Reuters in an interview.
'The industry is in a process of major consolidation and the M&A momentum is extremely high in vaccines because this area is strategically important,' he said.
'We are always looking for acquisition candidates,' Lanthaler said about his own company. 'Our focus is on ... products which are close to the final stadium (of approval).'
'In the current dynamics we don't necessarily always have to be the buyer, but could be the one who's bought up as well,' he added. 'We are not in takeover talks, however.'
(Reporting by Eva Komarek; Writing by Boris Groendahl; Editing by Louise Ireland) Keywords: INTERCELL/ tf.TFN-Europe_newsdesk@thomson.com ejp COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
'The industry is in a process of major consolidation and the M&A momentum is extremely high in vaccines because this area is strategically important,' he said.
'We are always looking for acquisition candidates,' Lanthaler said about his own company. 'Our focus is on ... products which are close to the final stadium (of approval).'
'In the current dynamics we don't necessarily always have to be the buyer, but could be the one who's bought up as well,' he added. 'We are not in takeover talks, however.'
(Reporting by Eva Komarek; Writing by Boris Groendahl; Editing by Louise Ireland) Keywords: INTERCELL/ tf.TFN-Europe_newsdesk@thomson.com ejp COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2008 AFX News
